Nasal congestion

KVUE Shareholders: Contact Robbins LLP About Your Rights and Remedies in the Kenvue Inc. Securities Fraud Class Action

Retrieved on: 
Thursday, October 19, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Nasal, Register, NYSE, Food, KVUE, Person, Registration statement, PE, LLP, Phenylephrine, Prospectus, Risk, Nasal congestion, Criticism of the Food and Drug Administration, Security (finance), Pharmaceutical industry, IPO

Kenvue Inc. operates as a consumer health company worldwide.

Key Points: 
  • Kenvue Inc. operates as a consumer health company worldwide.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on: 
Wednesday, October 18, 2023
Class Action Lawsuit, Professional Services, Legal, Suite, FDA, Nasal, Register, NYSE, KVUE, Registration statement, News, Court, PE, Phenylephrine, Prospectus, GPM, Nasal congestion, Risk, Johnson & Johnson, Defendant, Security (finance), Pharmaceutical industry, IPO

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • On this news, Kenvue’s stock declined by $1.01 per share, or 4.58%, to close at $21.06 on September 12, 2021, injuring investors.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.

KVUE Class Action Notice: Robbins LLP Reminds Informs Investors of Lead Plaintiff Deadline in Kenvue Inc. Securities Fraud Class Action

Retrieved on: 
Monday, October 16, 2023
NYSE, Food, LLP, Registration statement, Nasal congestion, Phenylephrine, Criticism of the Food and Drug Administration, Risk, Prospectus, FDA, Person, KVUE, Nasal, SAN, Register, PE, Security (finance), Pharmaceutical industry, IPO

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Kenvue Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by December 8, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Kenvue Inc.: Please contact the Portnoy Law Firm to recover your losses; December 8, 2023 deadline

Retrieved on: 
Saturday, October 14, 2023
NYSE, Registration statement, Nasal congestion, Phenylephrine, Defendant, Risk, Prospectus, Johnson & Johnson, Decongestant, FDA, KVUE, IPO, News, Register, PE, Security (finance), Pharmaceutical industry

LOS ANGELES, Oct. 13, 2023 (GLOBE NEWSWIRE) -- The Portnoy Law Firm advises Kenvue Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) investors that a lawsuit filed on behalf of investors that purchased Kenvue securities pursuant and/or traceable to the registration statement and related prospectus (collectively, the “Registration Statement”) issued in connection with the Company’s May 2023 initial public offering (the “IPO” or “Offering”).

Key Points: 
  • Investors are encouraged to contact attorney Lesley F. Portnoy , by phone 844-767-8529 or email : [email protected], to discuss their legal rights, or click here to join the case via www.portnoylaw.com .
  • The Portnoy Law Firm can provide a complimentary case evaluation and discuss investors’ options for pursuing claims to recover their losses.
  • However, shortly after the IPO, an FDA panel unanimously declared that oral forms of PE were ineffective in relieving nasal congestion.
  • The Portnoy Law Firm represents investors in pursuing claims against caused by corporate wrongdoing.

Shareholder Alert: Robbins LLP Informs Shareholders of Class Action Filed Against Kenvue Inc. (KVUE)

Retrieved on: 
Wednesday, October 11, 2023
NYSE, Food, LLP, Registration statement, Nasal congestion, Phenylephrine, Criticism of the Food and Drug Administration, Risk, Prospectus, FDA, Person, KVUE, Nasal, SAN, Register, PE, Security (finance), Pharmaceutical industry, IPO

For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.

Key Points: 
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Kenvue Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by December 8, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on: 
Monday, October 16, 2023
Class Action Lawsuit, Professional Services, Legal, NYSE, Telephone, Registration statement, Nasal congestion, Phenylephrine, Defendant, Court, Risk, Prospectus, Johnson & Johnson, Law, FDA, KVUE, Nasal, News, Register, PE, Suite, Security (finance), Pharmaceutical industry, IPO

Investors suffering losses on their Kenvue investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .

Key Points: 
  • Investors suffering losses on their Kenvue investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • On this news, Kenvue’s stock declined by $1.01 per share, or 4.58%, to close at $21.06 on September 12, 2021, injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of Kenvue Inc. (KVUE) Investors

Retrieved on: 
Friday, October 13, 2023
Class Action Lawsuit, Professional Services, Legal, NYSE, GPM, Registration statement, Phenylephrine, Nasal congestion, Defendant, Court, Risk, Prospectus, Johnson & Johnson, FDA, KVUE, Nasal, News, Register, PE, Suite, Security (finance), Pharmaceutical industry, IPO

Kenvue investors have until December 8, 2023 to file a lead plaintiff motion.

Key Points: 
  • Kenvue investors have until December 8, 2023 to file a lead plaintiff motion.
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • On this news, Kenvue’s stock declined by $1.01 per share, or 4.58%, to close at $21.06 on September 12, 2021, injuring investors.

Kenvue Inc. (KVUE) Investor Alert: Robbins LLP Informs Investors of Class Action Filed Against Kenvue Inc.

Retrieved on: 
Thursday, October 12, 2023
Professional Services, Class Action Lawsuit, NYSE, Food, LLP, Registration statement, Nasal congestion, Phenylephrine, Criticism of the Food and Drug Administration, Risk, Prospectus, FDA, Person, KVUE, Nasal, Register, PE, Security (finance), Pharmaceutical industry, IPO

Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons who purchased or otherwise acquired Kenvue Inc. (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Kenvue's initial public offering ("IPO").

Key Points: 
  • Robbins LLP reminds investors that a shareholder filed a class action lawsuit on behalf of persons who purchased or otherwise acquired Kenvue Inc. (NYSE: KVUE) securities pursuant and/or traceable to the registration statement and related prospectus issued in connection with Kenvue's initial public offering ("IPO").
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.
  • If you choose to take no action, you can remain an absent class member.

INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of Kenvue Inc. (KVUE) Investors

Retrieved on: 
Thursday, October 12, 2023
Class Action Lawsuit, Professional Services, Legal, NYSE, Telephone, Registration statement, Nasal congestion, Phenylephrine, Defendant, Risk, Prospectus, Johnson & Johnson, Law, FDA, KVUE, Nasal, News, Register, PE, Suite, Security (finance), Pharmaceutical industry, IPO

Kenvue investors have until December 8, 2023 to file a lead plaintiff motion.

Key Points: 
  • Kenvue investors have until December 8, 2023 to file a lead plaintiff motion.
  • Investors suffering losses on their Kenvue investments are encouraged to contact the Law Offices of Howard G. Smith to discuss their legal rights in this class action at 888-638-4847 or by email to [email protected] .
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • On this news, Kenvue’s stock declined by $1.01 per share, or 4.58%, to close at $21.06 on September 12, 2021, injuring investors.

The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Kenvue Inc. (KVUE) Investors

Retrieved on: 
Thursday, October 12, 2023
Class Action Lawsuit, Professional Services, Legal, NYSE, Registration statement, Nasal congestion, Phenylephrine, Defendant, Court, Risk, Prospectus, Johnson & Johnson, Law, FDA, Person, KVUE, Nasal, News, Register, PE, Suite, Security (finance), Pharmaceutical industry, IPO

Kenvue investors have until December 8, 2023 to file a lead plaintiff motion.

Key Points: 
  • Kenvue investors have until December 8, 2023 to file a lead plaintiff motion.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • On this news, Kenvue’s stock declined by $1.01 per share, or 4.58%, to close at $21.06 on September 12, 2021, injuring investors.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.